1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

SNPHF
Santen Pharmaceutical Co., Ltd.US flagOther OTC
13.05
USD
- -
- -
4.20BMarket Cap
Santen Pharmaceutical Co., Ltd.
SNPHF
(Other OTC)

Recent

price

13.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
259.41
262.64
282.26
354.41
391.79
471.96
485.19
553.48
576.18
605.16
624.86
666.02
720.24
822.75
860.39
- -
438.05
Revenue per Share
49.94
39.39
39.16
47.78
58.18
128.99
52.94
86.76
78.67
59.17
23.31
68.08
-38.58
72.59
103.98
- -
20.65
Basic EPS, GAAP
41.6
49.31
23.57
50.42
-99.39
32.46
3.27
80.97
60.47
76.96
37.56
25.52
32.42
168.82
- -
- -
110.59
Free Cash Flow per Basic Share
15.94
19.98
20.07
19.98
20.01
23.98
26.2
25.98
26.05
26
28.01
30
32.54
32.37
- -
- -
16.47
Dividend per Share
360.97
358.17
373.6
411.91
450.84
554.97
563.13
632.99
657.15
705.96
705.37
748.29
636.96
677.91
679.98
- -
734.19
Book Value per Share
363.82
348.88
344.33
389.16
308.3
426.13
285.11
376.62
397.53
457.74
485.25
516.86
508.46
603.65
601.45
- -
585.84
Tangible Book Value per Share
427
436
422
413
413
414
410
406
406
399
399
400
387
367
349
- -
356
Basic Weighted Avg Shares
110,812
114,416
119,066
146,260
161,831
195,291
199,096
224,942
234,026
241,555
249,605
266,257
279,037
301,965
300,004
291,624
156,159
Sales/Revenue/Turnover
27.74
23.36
20.73
20.43
21.86
41.06
16.31
17.2
19.27
13.88
4.88
13.48
-1.11
12.76
15.63
16.39
8.61
Operating Margin (%)
2,976
2,949
3,290
2,841
6,958
9,338
9,882
10,896
10,969
16,573
17,498
17,055
17,249
18,178
8,812
8,773
9,245
Depreciation Expense
21,333
17,160
16,520
19,718
24,032
53,373
21,724
35,261
31,954
23,618
9,311
27,218
-14,948
26,642
36,256
37,369
7,361
Net Income, GAAP
31.35
38.25
35.44
35.05
32.99
32.84
27.72
10.19
25.92
32.34
21.92
23.66
- -
10.61
24.49
20.83
22.98
Effective Tax Rate (%)
19.25
15
13.87
13.48
14.85
27.33
10.91
15.68
13.65
9.78
3.73
10.22
-5.36
8.82
12.09
12.81
4.71
Profit Margin (%)
113,564
112,863
102,426
114,055
94,332
121,509
103,530
121,166
134,079
150,959
127,682
133,605
123,822
143,343
137,463
140,890
134,610
Working Capital
152
115
87
59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
156,404
164,861
167,857
187,210
211,779
260,009
255,929
287,557
292,572
302,560
309,646
336,844
293,297
305,369
285,181
296,017
288,254
Total Equity
13.79
9.96
9.34
10.59
11.46
21.59
8.7
12.54
11.23
7.45
3.05
8.35
- -
11.28
11.84
12.87
9.95
Return on Invested Capital (%)
14.5
11.06
10.53
12.2
13.6
26.15
10.52
14.53
12.93
9.87
3.79
9.72
- -
11.72
15.99
16.59
10.83
Return on Capital (%)
14.52
11.06
10.53
12.04
13.49
25.67
9.43
14.44
12.19
8.61
3.3
9.37
-5.48
10.75
14.92
15.93
2.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
363
- -
349
Market Capitalization
513,554
558,715
606,183

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
236,139
- -
218,478
Cash, Cash Equivalents & STI
94,961
- -
85,918
Accounts Receivable, Net
90,539
- -
71,124
Inventories
43,185
- -
53,060
Total Current Liabilities
92,796
- -
83,868
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.54%
-0.57%
3.8%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-29.47%
-40.33%
3.07%
Sales/Revenue/Turnover
4.18%
3.25%
-2.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72,389
73,417
77,027
79,132
301,965
2025
- -
- -
- -
- -
300,004
2026
- -
- -
- -
- -
291,624

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
27.94
24.6
20.73
- -
72.59
2025
- -
- -
- -
- -
103.98
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15.88
0.24
16.36
- -
32.37
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
Zoetis Inc. (0M3Q.L)
Merck & Co., Inc. (MRK)
GSK plc (GLAXF)
Santen Pharmaceutical Co., Ltd. (SNPHY)
Daiichi Sankyo Company, Limited (4568.T)
Business
Santen Pharmaceutical Co., Ltd. is a global leader dedicated to the research, development, manufacturing, and commercialization of specialized pharmaceuticals and cutting-edge medical devices primarily within ophthalmology. The company extends its reach across Japan, Europe, Asia, and North America, delivering innovative solutions for various eye conditions. Their comprehensive portfolio includes prescription treatments for prevalent conditions such as glaucoma and ocular hypertension, exemplified by the recent Japanese launch of SETANEO® Ophthalmic Solution. Santen also offers therapies for dry eye, including the re-initiated shipments of DIQUAS LX Ophthalmic Solution 3%, alongside medications targeting allergic conjunctivitis and uveitis. A significant area of ongoing development focuses on myopia, with late-stage programs like atropine sulfate having launched in Europe and in clinical trials across Asia, aiming to address the progression of juvenile myopia. The company is also exploring treatments for conditions like Fuchs endothelial corneal dystrophy and diabetic macular edema, the latter through a partnership with RemeGen for RC28-E intravitreal injection which recently had its Biologic License Application accepted in China. Beyond prescription medicines, Santen provides a range of over-the-counter ophthalmic products for general eye care and supplies medical devices, including intraocular lenses and the PRESERFLO™ MicroShunt for glaucoma management, approved in Canada and distributed in the U.S. through a Glaukos agreement. Established in Osaka, Japan, in 1890, Santen Pharmaceutical continues its legacy of focusing on eye health, driven by a strategic vision to achieve global leadership in ophthalmology by addressing unmet patient needs worldwide.